Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Public ClinicalTrials.gov record NCT05238116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Study identification
- NCT ID
- NCT05238116
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2022 (Actual)
- Primary completion
- Dec 29, 2025 (Actual)
- Completion
- Dec 29, 2025 (Actual)
- Last update posted
- Apr 30, 2026
2022 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Site | La Jolla | California | 92037 | — |
| Clinical Research Site | Los Angeles | California | 90048 | — |
| Clinical R Site | Los Angeles | California | 90095 | — |
| Clinical Research Site | Sacramento | California | 95817 | — |
| Clinical Research Site | Jacksonville | Florida | 32224 | — |
| Clinical Research Site | Baltimore | Maryland | 21287 | — |
| Clinical Research Site | Ann Arbor | Michigan | 48109 | — |
| Clinical Research Site | Minneapolis | Minnesota | 55455 | — |
| Clinical Research Site | St Louis | Missouri | 63110 | — |
| Clinical Research Site | The Bronx | New York | 10467 | — |
| Clinical Research Site | Philadelphia | Pennsylvania | 19014 | — |
| Clinical Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Research Site 1 | Houston | Texas | 77030 | — |
| Clinical Research Site 2 | Houston | Texas | 77030 | — |
| Clinical Research Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05238116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05238116 live on ClinicalTrials.gov.